189 related articles for article (PubMed ID: 30160782)
1. Association between HLA-DQA1/DRB1 polymorphism and development of hepatocellular carcinoma during entecavir treatment.
Kozuka R; Enomoto M; Sato-Matsubara M; Yoshida K; Motoyama H; Hagihara A; Fujii H; Uchida-Kobayashi S; Morikawa H; Tamori A; Kawada N; Murakami Y
J Gastroenterol Hepatol; 2019 May; 34(5):937-946. PubMed ID: 30160782
[TBL] [Abstract][Full Text] [Related]
2. Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection.
Yamada R; Hiramatsu N; Oze T; Morishita N; Harada N; Yakushijin T; Iio S; Doi Y; Yamada A; Kaneko A; Hagiwara H; Mita E; Oshita M; Itoh T; Fukui H; Hijioka T; Katayama K; Tamura S; Yoshihara H; Imai Y; Kato M; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hamasaki T; Hayashi N; Takehara T;
J Gastroenterol; 2015 Jul; 50(7):785-94. PubMed ID: 25384794
[TBL] [Abstract][Full Text] [Related]
3. Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients.
Sou FM; Hu TH; Hung CH; Lai HC; Wang JH; Lu SN; Peng CY; Chen CH
Hepatol Int; 2020 Jul; 14(4):513-520. PubMed ID: 32319045
[TBL] [Abstract][Full Text] [Related]
4. Partial Virological Response after 2 Years of Entecavir Therapy Increases the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Associated Cirrhosis.
Shin SK; Yim HJ; Kim JH; Lee CU; Yeon JE; Suh SJ; Jung YK; Kim YS; Kim JH; Kwon OS
Gut Liver; 2021 May; 15(3):430-439. PubMed ID: 33115966
[TBL] [Abstract][Full Text] [Related]
5. Relationship of HLA-DRB1 alleles with hepatocellular carcinoma development in chronic hepatitis B patients.
Jin YJ; Shim JH; Chung YH; Kim JA; Choi JG; Park WH; Lee D; Lee YS; Kim SE; Kim SH; Yang SH
J Clin Gastroenterol; 2012; 46(5):420-6. PubMed ID: 22499074
[TBL] [Abstract][Full Text] [Related]
6. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
[TBL] [Abstract][Full Text] [Related]
7. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Tanaka J
J Gastroenterol Hepatol; 2017 Feb; 32(2):451-458. PubMed ID: 27288655
[TBL] [Abstract][Full Text] [Related]
8. HLA-DQA1 & DQB1 variants associated with hepatitis B virus-related chronic hepatitis, cirrhosis & hepatocellular carcinoma.
Karra VK; Chowdhury SJ; Ruttala R; Gumma PK; Polipalli SK; Chakravarti A; Kar P
Indian J Med Res; 2018 Jun; 147(6):573-580. PubMed ID: 30168489
[TBL] [Abstract][Full Text] [Related]
9. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.
Hosaka T; Suzuki F; Kobayashi M; Seko Y; Kawamura Y; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
Hepatology; 2013 Jul; 58(1):98-107. PubMed ID: 23213040
[TBL] [Abstract][Full Text] [Related]
10. Impacts of human leukocyte antigen DQ genetic polymorphisms and their interactions with hepatitis B virus mutations on the risks of viral persistence, liver cirrhosis, and hepatocellular carcinoma.
Ji X; Zhang Q; Li B; Du Y; Yin J; Liu W; Zhang H; Cao G
Infect Genet Evol; 2014 Dec; 28():201-9. PubMed ID: 25281206
[TBL] [Abstract][Full Text] [Related]
11. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
[TBL] [Abstract][Full Text] [Related]
12. The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B.
Kim BG; Park NH; Lee SB; Jeon S; Park JH; Jung SW; Jeong ID; Bang SJ; Shin JW
Liver Int; 2018 Dec; 38(12):2269-2276. PubMed ID: 30052303
[TBL] [Abstract][Full Text] [Related]
13. Genetic variations in STAT4,C2,HLA-DRB1 and HLA-DQ associated with risk of hepatitis B virus-related liver cirrhosis.
Jiang DK; Ma XP; Wu X; Peng L; Yin J; Dan Y; Huang HX; Ding DL; Zhang LY; Shi Z; Zhang P; Yu H; Sun J; Lilly Zheng S; Deng G; Xu J; Liu Y; Guo J; Cao G; Yu L
Sci Rep; 2015 Nov; 5():16278. PubMed ID: 26538132
[TBL] [Abstract][Full Text] [Related]
14. Rapid Alanine Aminotransferase Normalization with Entecavir and Hepatocellular Carcinoma in Hepatitis B Virus-Associated Cirrhosis.
Kim EJ; Yeon JE; Kwon OS; Lee HN; Shin SK; Kang SH; Byun KS; Kim JH; Kwon SY; Suh SJ; Yim HJ; Kim YS; Kim JH
Dig Dis Sci; 2017 Mar; 62(3):808-816. PubMed ID: 28035553
[TBL] [Abstract][Full Text] [Related]
15. Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection.
Matsuura K; Sawai H; Ikeo K; Ogawa S; Iio E; Isogawa M; Shimada N; Komori A; Toyoda H; Kumada T; Namisaki T; Yoshiji H; Sakamoto N; Nakagawa M; Asahina Y; Kurosaki M; Izumi N; Enomoto N; Kusakabe A; Kajiwara E; Itoh Y; Ide T; Tamori A; Matsubara M; Kawada N; Shirabe K; Tomita E; Honda M; Kaneko S; Nishina S; Suetsugu A; Hiasa Y; Watanabe H; Genda T; Sakaida I; Nishiguchi S; Takaguchi K; Tanaka E; Sugihara J; Shimada M; Kondo Y; Kawai Y; Kojima K; Nagasaki M; Tokunaga K; Tanaka Y;
Gastroenterology; 2017 May; 152(6):1383-1394. PubMed ID: 28163062
[TBL] [Abstract][Full Text] [Related]
16. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy.
Wang HW; Lai HC; Hu TH; Su WP; Lu SN; Lin CH; Hung CH; Chuang PH; Wang JH; Lee MH; Chen CH; Peng CY
J Gastroenterol Hepatol; 2019 Feb; 34(2):442-449. PubMed ID: 29968933
[TBL] [Abstract][Full Text] [Related]
17. Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B.
Lee J; Yoo SH; Sohn W; Kim HW; Choi YS; Won JH; Heo JY; Park SJ; Park YM
Clin Mol Hepatol; 2016 Sep; 22(3):339-349. PubMed ID: 27729627
[TBL] [Abstract][Full Text] [Related]
18. Prediction of risk for hepatocellular carcinoma by response of serum α-fetoprotein to entecavir therapy.
Yang SW; Kim GH; Chung JW; Sohn HR; Lee SS; Hong S; Chung SM; Jang ES; Jeong SH; Kim JW
J Gastroenterol Hepatol; 2015 Jul; 30(7):1175-82. PubMed ID: 25707935
[TBL] [Abstract][Full Text] [Related]
19. Independent and additive interaction between tumor necrosis factor β +252 polymorphisms and chronic hepatitis B and C virus infection on risk and prognosis of hepatocellular carcinoma: a case-control study.
Jeng JE; Wu HF; Tsai MF; Tsai HR; Chuang LY; Lin ZY; Hsieh MY; Chen SC; Chuang WL; Wang LY; Yu ML; Dai CY; Tsai JF
Asian Pac J Cancer Prev; 2014; 15(23):10209-15. PubMed ID: 25556449
[TBL] [Abstract][Full Text] [Related]
20. A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir.
Chiang HH; Lee CM; Hu TH; Hung CH; Wang JH; Lu SN; Lai HC; Su WP; Lin CH; Peng CY; Chen CH
Liver Int; 2018 Nov; 38(11):1997-2005. PubMed ID: 29797410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
